Wal-Mart's shockingly cheap drug plan
The retailer partners with Humana to beat out other plans for Medicare recipients.
Wal-Mart (WMT) upended the drug industry in 2006 by offering $4 generic drugs. Now the retailing giant is at it again, unveiling the cheapest prescription drug plan in the country.
Wal-Mart has partnered with health insurance company Humana (HUM) and will offer the plan to people on Medicare, Bloomberg reports. Starting Jan. 1, the plan will cost only $14.80 a month -- less than half the average Medicare premium for prescription drugs.
It's a win-win for both companies. Humana wants to boost its market share and hopes Wal-Mart will bring in enough business to keep its drug plans profitable. Wal-Mart wants more people to visit its pharmacies instead of Walgreens (WAG) or CVSCaremark (CVS).
The companies said the typical Medicare prescription-drug customer could save $450 a year with the new plan, which also has lower copayments and cost shares, according to Dow Jones Newswires. At specific pharmacies -- such as, oh, say, Wal-Mart's -- the copayment could be as low as $2 for generic drugs. Humana's mail-order service will have zero copay.
Already analysts predict a price war as other retailers and drugstores scramble to match Wal-Mart's pricing. "We would not be surprised if rival insurers form joint plans with other pharmacy chains," said Standard & Poor's analyst Phillip Seligman, according to Dow Jones.
People can enroll in the new plan from Nov. 15 through the end of the year. Click here for more information.
Post continues after video:
About 18 million Medicare beneficiaries have signed up for prescription-drug-only plans, Reuters reported.
More from MSN Top Stocks:
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
Traders might want to bite on BABA, but long-term investors have reasons to wait.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.